Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Enero 2024 - 3:01PM
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that
it will present at the 42nd Annual J.P. Morgan Healthcare
Conference on Monday, January 8, 2024 at 1:30 p.m. Pacific
Time (4:30 p.m. Eastern Time).
A live webcast of Kiniksa’s presentation will be accessible
through the Investors & Media section of the company’s website
at www.kiniksa.com. A replay of the webcast will also be available
on Kiniksa’s website within approximately 48 hours after the
event.
About KiniksaKiniksa is a commercial-stage
biopharmaceutical company focused on discovering, acquiring,
developing, and commercializing therapeutic medicines for patients
suffering from debilitating diseases with significant unmet medical
need. Kiniksa’s immune-modulating assets, ARCALYST, KPL-404, and
mavrilimumab, are based on strong biologic rationale or validated
mechanisms, target a spectrum of underserved cardiovascular and
autoimmune conditions, and offer the potential for differentiation.
For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron
Pharmaceuticals, Inc.
Every Second Counts! ®
Kiniksa Investor and Media ContactRachel
Frank(339) 970-9437rfrank@kiniksa.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Gráfica de Acción Histórica
De May 2023 a May 2024